CLINICAL_TRIALS
trial_result
· 2016-08-05
Clinical Trial Update: Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML) [Phase 3]
Summary
An update on a Phase 3 expanded-access study of peginterferon alfa-2a (Pegasys) for chronic myeloid leukemia, with results posted in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hoffmann-La Roche | Conditions: Myelogenous Leukemia, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2016-08-05